Brokerages Set Zura Bio Limited (NASDAQ:ZURA) PT at $10.75

Zura Bio Limited (NASDAQ:ZURA) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $10.75.

Several research analysts recently commented on the stock. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Tuesday, October 14th.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Scientech Research LLC bought a new position in shares of Zura Bio in the third quarter valued at $45,000. Forefront Wealth Partners LLC acquired a new stake in Zura Bio in the third quarter valued at $93,000. Squarepoint Ops LLC bought a new position in shares of Zura Bio in the 3rd quarter valued at about $109,000. Qube Research & Technologies Ltd acquired a new position in shares of Zura Bio during the 3rd quarter worth about $138,000. Finally, Savant Capital LLC raised its holdings in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after purchasing an additional 21,249 shares during the period. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $4.83 on Friday. The stock has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $2.86. Zura Bio has a 52-week low of $0.97 and a 52-week high of $5.75. The company has a market cap of $314.05 million, a PE ratio of -7.43 and a beta of 0.20.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). On average, research analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.